HMG CoA reductase inhibitors, commonly known as statins, were dispensed in half of the individuals of the dyslipidaemia & endocrine-metabolic patterns (in both four-year follow-up periods) while in the “hypertensive” patterns the prevalence was between 13 and 16% in the first and the second four-year follow-up, respectively. This evidence concerns the gene HMGCR and inherited lipid metabolism disorder.